Open access
Open access
Powered by Google Translator Translator

Allergy & Immunology

RCT | Dupilumab improves lung function and reduces exacerbations in COPD patients with elevated eosinophils

1 Jun, 2023 | 12:20h | UTC

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Dupilumab Improves Outcomes for COPD, Type 2 Inflammation in Randomized Trial – HCP Live

 

Commentary on Twitter

 


Guideline | Investigation and management of acute transfusion reactions

29 May, 2023 | 11:02h | UTC

Guideline on the investigation and management of acute transfusion reactions – British Journal of Haematology

 


RCT | Peanut patch therapy is effective in desensitizing young children with allergies, but raises risk of serious adverse events

15 May, 2023 | 13:10h | UTC

Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Cohort Study | Autoimmune disorders’ incidence, prevalence & co-occurrence by age, sex, and socioeconomic status

8 May, 2023 | 13:14h | UTC

Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK – The Lancet (free for a limited period)

 

Commentary from the author on Twitter (thread – click for more)

 


Cohort Study | Idiopathic CD4 Lymphocytopenia linked to increased infection risk and cancer prevalence

5 May, 2023 | 15:16h | UTC

Reappraisal of Idiopathic CD4 Lymphocytopenia at 30 Years – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT | Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis

3 May, 2023 | 15:04h | UTC

Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial – JAMA Dermatology

Commentary: Tralokinumab Efficacious, Well-Tolerated for Adolescents with Atopic Dermatitis – HCP Live

 

Commentary on Twitter

 


Immediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist

24 Apr, 2023 | 13:40h | UTC

Immediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist- Cancer Treatment Reviews (free for a limited period)

See Tweet from one of the authors with infographic and link to free full text here

 


Identifying perioperative anaphylaxis in Japan: epidemiology, allergens, and diagnostic tools

17 Apr, 2023 | 13:10h | UTC

The Japanese Epidemiologic Study for Perioperative Anaphylaxis, a prospective nationwide study: allergen exposure, epidemiology, and diagnosis of anaphylaxis during general anaesthesia – British Journal of Anaesthesia

 


M-A | Timing of allergenic food introduction and risk of immunoglobulin E–mediated food allergy

11 Apr, 2023 | 14:32h | UTC

Timing of Allergenic Food Introduction and Risk of Immunoglobulin E–Mediated Food Allergy: A Systematic Review and Meta-analysis – JAMA Pediatrics

News Release: Earlier introduction of allergenic foods in children may prevent food allergies – Imperial College London

Commentary: Allergenic Food Introduction Led to Fewer Allergies, Higher Withdrawal Rate from Intervention – HCP Live

Related:

Study | Public health policies should recommend introducing peanut products to infants at 4-6 months of age to prevent peanut allergy

AAP Updated Recommendations for Dietary Interventions to Prevent Atopic Disease

Timing of introduction of allergenic solids for infants at high risk – Canadian Paediatric Society

 

Commentary on Twitter

 


RCT | Baricitinib + topical corticosteroids effective in kids with moderate-severe atopic dermatitis

4 Apr, 2023 | 13:39h | UTC

Efficacy and safety of baricitinib in combination with topical corticosteroids in pediatric patients with moderate-to-severe atopic dermatitis with inadequate response to topical corticosteroids: results from a phase 3, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS) – British Journal of Dermatology

 


Cohort Study | Associations between fetal or infancy pet exposure and food allergies

3 Apr, 2023 | 13:26h | UTC

Associations between fetal or infancy pet exposure and food allergies: The Japan Environment and Children’s Study – PLOS One

 


RCT | Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention

31 Mar, 2023 | 13:26h | UTC

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

 

Commentary on Twitter (thread – click for more)

 


Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis

21 Mar, 2023 | 13:23h | UTC

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Largest study to date of lebrikizumab supports its use for treatment of atopic dermatitis – George Washington University

Commentary: Lebrikizumab Effective for Adults, Teens With Atopic Dermatitis – HealthDay

 


Study | Public health policies should recommend introducing peanut products to infants at 4-6 months of age to prevent peanut allergy

20 Mar, 2023 | 13:33h | UTC

Defining the window of opportunity and target populations to prevent peanut allergy – Journal of Allergy and Clinical Immunology

Commentary: Expert reaction to research on giving peanut products to babies – Science Media Centre

Related study: Early Introduction of Allergenic Foods Can Prevent Food Allergies in High Risk Infants

Related Guidelines: 

AAP Updated Recommendations for Dietary Interventions to Prevent Atopic Disease

Timing of introduction of allergenic solids for infants at high risk – Canadian Paediatric Society

 

Commentary from the author on Twitter

 


Cohort Study | Leukotriene-receptor antagonist use during pregnancy not linked to neuropsychiatric events in offspring

17 Mar, 2023 | 12:56h | UTC

Use of Leukotriene-Receptor Antagonists During Pregnancy and Risk of Neuropsychiatric Events in Offspring – JAMA Network Open

Commentary: In utero exposure to asthma medication not tied to risks of neurodevelopmental disorders – MDedge

 


International consensus statement on allergy and rhinology: allergic rhinitis

16 Mar, 2023 | 13:19h | UTC

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023 – International Forum of Allergy & Rhinology

 


Drug allergy | A 2022 practice parameter update

3 Mar, 2023 | 13:59h | UTC

Drug allergy: A 2022 practice parameter update – The Journal of Allergy and Clinical Immunology

 


Antibiotic allergy de-labeling: a pathway against antibiotic resistance

23 Feb, 2023 | 13:12h | UTC

Antibiotic Allergy De-Labeling: A Pathway against Antibiotic Resistance – Antibiotics

Related:

Improving antimicrobial stewardship with penicillin allergy testing: a review of current practices and unmet needs – JAC-Antimicrobial Resistance

Management of Patients with Suspected or Confirmed Antibiotic Allergy. Executive Summary of Guidance from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Allergy and Clinical Immunology (SEAIC), the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Intensive Medicine and Coronary Care Units (SEMICYUC) – Journal of Investigational Allergology and Clinical Immunology (PDF)

The prevalence of penicillin allergy labeling ranged from 0.9% to 10.2% across practices in a large pediatric cohort, raising questions regarding the validity of those labels and the unnecessary use of second-line antibiotics that may follow.

The prevalence of penicillin allergy labeling ranged from 0.9% to 10.2% across practices in a large pediatric cohort, raising questions regarding the validity of those labels and the unnecessary use of second-line antibiotics that may follow.

M-A: Most patients with allergy to Penicillin can be given Cefazolin

Systematic review: Safety and efficacy of de-labelling penicillin allergy in adults using direct oral challenge

Penicillin allergy labels increase second-line broad-spectrum antibiotic prescribing for pediatric respiratory tract infections

Podcast: A Clinical Pharmacologist’s Perspective on Penicillin Allergy

Study: Development and Validation of a Penicillin Allergy Clinical Decision Rule

Management of a surgical patient with a label of penicillin allergy: narrative review and consensus recommendations – British Journal of Anaesthesia

NICE: Double Check Patients with ‘Penicillin Allergy’ to Avoid Increased MRSA Risk

Cohort Study: Risk of Meticillin Resistant Staphylococcus Aureus and Clostridium Difficile in Patients with a Documented Penicillin Allergy

 


M-A | Worldwide prevalence of antibiotic-associated Stevens-Johnson syndrome and toxic epidermal necrolysis

16 Feb, 2023 | 15:04h | UTC

Summary: The article examined the prevalence Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) associated with antibiotics worldwide. The analysis included 38 studies involving 2,917 patients, which showed that 28% of SJS/TEN cases were associated with antibiotics. Among antibiotic-associated SJS/TEN, the sulfonamide class was associated with 32% of cases, followed by penicillins, cephalosporins, fluoroquinolones, and macrolides.

Article: Worldwide Prevalence of Antibiotic-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis – JAMA Dermatology (free for a limited period)

 

*Note: This summary was created through the collaboration of a medical editor and ChatGPT.

 


Phase 2 RCT | Effects of Difelikefalin in notalgia paresthetica

13 Feb, 2023 | 12:42h | UTC

Phase 2 Trial of Difelikefalin in Notalgia Paresthetica – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

Phase 2 Trial Finds Difelikefalin Could Prove Useful in Notalgia Paresthetica – HCP Live

Difelikefalin Improves Itch Intensity in Notalgia Paresthetica – HealthDay

 

Commentary on Twitter

 


RCT | Effectiveness of Mycophenolate Mofetil among patients with progressive IgA nephropathy

10 Feb, 2023 | 13:52h | UTC

Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial – JAMA Network Open

 

Commentary on Twitter

 


RCT | Methylprednisolone vs. immunoglobulins equally effective in PIMS temporally associated with SARS-CoV-2

8 Feb, 2023 | 12:42h | UTC

Methylprednisolone versus intravenous immunoglobulins in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): an open-label, multicentre, randomised trial – The Lancet Child & Adolescent Health

 


Phase 2b RCT | An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis

8 Feb, 2023 | 12:22h | UTC

An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study – The Lancet (link to abstract – $ for full-text)

News Release: New Treatment for Moderate to Severe Atopic Dermatitis Shows Promising Long-Term Results – Mount Sinai Health System

Commentary: Rocatinlimab Effective for Moderate-to-Severe Atopic Dermatitis – HealthDay

 

Commentary on Twitter:

 


Guideline | Urticaria management

6 Feb, 2023 | 13:25h | UTC

Part 1: Classification and diagnosis of urticaria – German-language adaptation of the international S3 Guideline – Journal of the German Dermatological Society

Part 2: Treatment of urticaria – German-language adaptation of the international S3 guideline – Journal of the German Dermatological Society

 


Patients labeled as nonallergic after initial tests for penicillin allergy may develop resensitization afterwards

2 Feb, 2023 | 15:03h | UTC

Resensitization in suspected penicillin allergy – Allergy

Video summary: Resensitisation in suspected penicillin allergy

Commentary: Patients should be retested for penicillin resensitization before being deemed nonallergic – Healio (free registration required)

Related:

Improving antimicrobial stewardship with penicillin allergy testing: a review of current practices and unmet needs – JAC-Antimicrobial Resistance

Management of Patients with Suspected or Confirmed Antibiotic Allergy. Executive Summary of Guidance from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Allergy and Clinical Immunology (SEAIC), the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Intensive Medicine and Coronary Care Units (SEMICYUC) – Journal of Investigational Allergology and Clinical Immunology (PDF)

The prevalence of penicillin allergy labeling ranged from 0.9% to 10.2% across practices in a large pediatric cohort, raising questions regarding the validity of those labels and the unnecessary use of second-line antibiotics that may follow.

The prevalence of penicillin allergy labeling ranged from 0.9% to 10.2% across practices in a large pediatric cohort, raising questions regarding the validity of those labels and the unnecessary use of second-line antibiotics that may follow.

M-A: Most patients with allergy to Penicillin can be given Cefazolin

Systematic review: Safety and efficacy of de-labelling penicillin allergy in adults using direct oral challenge

Penicillin allergy labels increase second-line broad-spectrum antibiotic prescribing for pediatric respiratory tract infections

Podcast: A Clinical Pharmacologist’s Perspective on Penicillin Allergy

Study: Development and Validation of a Penicillin Allergy Clinical Decision Rule

Management of a surgical patient with a label of penicillin allergy: narrative review and consensus recommendations – British Journal of Anaesthesia

NICE: Double Check Patients with ‘Penicillin Allergy’ to Avoid Increased MRSA Risk

Cohort Study: Risk of Meticillin Resistant Staphylococcus Aureus and Clostridium Difficile in Patients with a Documented Penicillin Allergy

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts US$ 7.00/month

No spam, just news.